GlassScriptPhysician profile
Brett A Buller
NPI 1861709925
$2,555.08
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $357 · 2021: $204 · 2022: $278 · 2023: $320 · 2024: $401 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $569.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $421.87 | 2019-2024 | |
| Novo Nordisk INC | $218.17 | 2019-2024 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $183.46 | 2019-2025 | Arexvy, Shingrix |
| Abbvie INC. | $145.62 | 2021-2023 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $130.28 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $98.91 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.69 | 2019-2025 | Ofev, Jardiance |
| Amgen INC. | $87.50 | 2019-2024 | Prolia, Evenity |
| Xeris Pharmaceuticals, INC. | $71.61 | 2022-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $71.43 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $71.24 | 2019-2022 | |
| Astellas Pharma US INC | $57.59 | 2024-2025 | Veozah |
| Abbott Laboratories | $54.29 | 2019-2025 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $37.52 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.93 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.02 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $32.49 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $23.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2019 | |
| Sanofi Pasteur INC. | $19.43 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $18.11 | 2025 | |
| Avanir Pharmaceuticals, INC. | $16.88 | 2019 | |
| Dexcom, INC. | $14.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Buller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.